Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: X-ray Vision who wrote (2097)	1/30/2000 1:05:00 AM
From: out_of_the_loop	Read Replies (1) \| Respond to of 5582

Well, I bought more on Friday but not a lot relative to my position. The reasons include the sustained increase in volume probably does indicate an institutional buyin, and this must be for a good reason. I think the patent for Zicam probably boots all (if there ever was ANY) credibility to the QGLY suit. I would say that the pros are that news (clinicals, profitable quarter numbers, Swedish Match final touches) are extremely likely and the cons are the incredible run of 17/18 days up and the fact that you never know how the market treats news. If it were my position, I would consider a 5-20% increase in position, depending on your tolerance of risk - you know mine is high, Terry - lol. Anyway, I am very bullish on this company and the above decision could be modified upward if you were not highly margined and you were able to look at more than the next week or two or three for evaluating your investment decision.